SCHEMBL3485175

SCHEMBL3485175

CN1[C@@H]2CCC[C@@]1(OC(c1ccccc1)c1ccccc1)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.42
SLC6A2 P23975 3/20 0.42
CHRM2 P08172 2/20 0.42
ADRA2A P08913 2/20 0.42
CHRM1 P11229 2/20 0.42
DRD1 P21728 2/20 0.42
ADRA1A P35348 2/20 0.42
OPRM1 P35372 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KCNH2 Q12809 2/20 0.42
DRD2 P14416 2/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
CHRM3 P20309 1/20 0.42
HRH2 P25021 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4152474 0.99 DRD3 (0.41) DRD3SLC6A2CHRM2ADRA2ACHRM1
Hydrochloric Acid SCHEMBL6678403 0.91 MEN1 (0.50) DRD3SLC6A2CHRM2ADRA2ACHRM1
SCHEMBL1231002 0.88 CYP2D6 (0.51) DRD3SLC6A2CHRM2ADRA2ACHRM1
Hydrochloric Acid SCHEMBL6677281 0.85 SLC6A3 (0.46) DRD3SLC6A2CHRM2ADRA2ACHRM1
SCHEMBL5793665 0.75 CYP2D6 (0.39) CHRM2CHRM1ADRA1ACHRM4CHRM5
SCHEMBL9640284 0.72 CHRM2 (0.46) CHRM2CHRM1CHRM4CHRM3MEN1
SCHEMBL9678183 0.71 TSHR (0.40) ADRA1AOPRM1ADRA1DOPRD1OPRK1
SCHEMBL5790059 0.69 ALDH1A1 (0.40) MAPK1MAPTTSHRKMT2ALMNA
SCHEMBL7356174 0.69 HRH3 (0.37) CHRM2CHRM1DRD2CHRM4CHRM5
SCHEMBL4538423 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170112829-A1 USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-04-27 US claimed
US-20090325975-A1 Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-12-31 US claimed
US-20170112829-A1 USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-04-27 US disclosed
EP-2964611-A2 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2016-01-13 EP disclosed
EP-2925309-A1 SUBSTITUTED BENZTROPINE ANALOGS FOR TREATMENT OF DEMENTIA P2D, Inc. (US) 2015-10-07 EP disclosed
US-20140350081-A1 INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME US ARMY, SECRETARY OF THE ARMY 2014-11-27 US disclosed
WO-2014138518-A2 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2014-09-12 WO disclosed
WO-2014085367-A1 SUBSTITUTED BENZTROPINE ANALOGS FOR TREATMENT OF DEMENTIA P2D INC. (US) 2014-06-05 WO disclosed
WO-2013067519-A2 INSECT AND TICK G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME PURDUE RESEARCH FOUNDATION (US) 2013-05-10 WO disclosed
US-20100009340-A1 COMPOSITIONS AND METHODS FOR THE ANALYSIS AND TREATMENT OF AIDS WASTING SYNDROME AND IMMUNE CELL DYSFUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-01-14 US disclosed
US-20090325975-A1 Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-12-31 US disclosed
EP-1624845-A2 4',4''-SUBSTITUTED 3ALPHA-(DIPHENYLMETHOXY)TROPANE ANALOGS FOR TREATMENT OF MENTAL DISORDERS Phase 2 Discovery, Inc. (US) 2006-02-15 EP disclosed
WO-2005107467-A2 COMPOSITIONS INCLUDING OPIOIDS AND METHODS OF THEIR USE IN TREATING PAIN DESCARTES THERAPEUTICS, INC. (US) 2005-11-17 WO disclosed
WO-2004062610-A2 4',4''-SUBSTITUTED 3α-(DIPHENYLMETHOXY)TROPANE ANALOGS FOR TREATMENT OF MENTAL DISORDERS PHASE 2 DISCOVERY, INC. (US) 2004-07-29 WO disclosed
WO-1997040859-A1 BRIDGE-SUBSTITUTED TROPANES AND USES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1997-11-06 WO disclosed
WO-1994004146-A1 COCAINE ANALOGUES AND THEIR USE AS COCAINE DRUG THERAPIES AND THERAPEUTIC AND IMAGING AGENTS FOR NEURODEGENERATIVE DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1994-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350081-A1 INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME DDT, ADRA2C, MCHR1 DRD3 15/4885SLC6A2 24/4885CHRM2 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.